| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/28/2005 | WO2005002522A3 Compositions and methods for treating tissue ischemia |
| 04/28/2005 | WO2005002495A3 Use of plasma membrane calcium atpase (pmca) inhibitors for inhibiting sperm mobility |
| 04/28/2005 | WO2005000282A3 Inhibitors of histone deacetylases for the suppression therapy of diseases |
| 04/28/2005 | WO2005000243A3 The polymorphic form a of 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butryric acid |
| 04/28/2005 | WO2005000232A3 Six membered amino-amide derivatives as angiogenesis inhibitors |
| 04/28/2005 | WO2004110351A3 Heterocyclic compounds for treating hepatitis c virus |
| 04/28/2005 | WO2004108682A3 Tetrahydroisoquinolines as antagonists of the 5ht1b receptor |
| 04/28/2005 | WO2004108139A8 Use of fused heterocyclic compounds as scce inhibitors for the treatment of skin conditions or cancer |
| 04/28/2005 | WO2004106299A3 Substituted pyrrole derivatives and their use as hmg-co inhibitors |
| 04/28/2005 | WO2004099213A3 Pyrrolo (1,2-b) pyridazine compounds and their use as crf-1 receptor antagonists |
| 04/28/2005 | WO2004098634A3 Protein arginine n-methyltransferase 2 (prmt-2) |
| 04/28/2005 | WO2004098531A3 Increased transduction using abc transporter substrates and/or inhibitors |
| 04/28/2005 | WO2004093817A3 Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| 04/28/2005 | WO2004089293A3 Hydroxamic acid compounds and methods of use thereof |
| 04/28/2005 | WO2004084905A3 Use of 5-ht2c receptor activity affecting compounds for treating idiopathic hyperhidrosis and associated conditions |
| 04/28/2005 | WO2004075893A8 Method of treatment of cardiac and/or renal failure using a calcium channel blocker and an angiotensin converting enzyme inhibitor or an angiotensin ii receptor blocker |
| 04/28/2005 | WO2004071437A3 Compositions for enhancing sexual responsiveness |
| 04/28/2005 | WO2004065539A3 Androgen receptor antagonists |
| 04/28/2005 | WO2004064759A3 Use of tryptanthrin compounds for immune potentiation |
| 04/28/2005 | WO2004060378A8 Compositions comprising particles containing alumina with compounds bound to the alumina surface, delivery systems and methods of preparation thereof |
| 04/28/2005 | WO2004050833A3 Glyceraldehyde 3-phosphate dehydrogenase-s(gapds), a glycolytic enzyme expressed only in male germ cells,is a target for male contraception |
| 04/28/2005 | WO2004048524A3 Modulation of stat2 expression |
| 04/28/2005 | WO2004035000A3 Enhancement of sleep with t-type calcium channel antagonists |
| 04/28/2005 | WO2004014844A3 Aryl and heteroaryl compounds and methods to modulate coagulation |
| 04/28/2005 | WO2004014842A8 Acylated arylcycloalkylamines and their use as pharmaceuticals |
| 04/28/2005 | WO2004005262A8 New neuropeptide y y5 receptor antagonists |
| 04/28/2005 | WO2003101425A8 Therapeutic agent-containing polymeric nanoarticles |
| 04/28/2005 | WO2003099201A3 Compositions and methods of use for a fibroblast growth factor |
| 04/28/2005 | WO2003095971A3 Posh nucleic acids, polypeptides and related methods |
| 04/28/2005 | WO2003089597A3 Use of cox-2 inhibitors to prevent recurrences of herpesvirus infections |
| 04/28/2005 | WO2003087389A3 Biologic modulations with nanoparticles |
| 04/28/2005 | WO2003086283A9 Metastasis modulating activity of highly sulfated oligosaccharides |
| 04/28/2005 | WO2003072067A3 Compositions and methods for treating epithelial and retinal tissue diseases |
| 04/28/2005 | WO2003068929A3 Methods of inhibiting hiv-1 vpr activity and hiv-1 infectivity using atr or rad17 inhibitors |
| 04/28/2005 | WO2003044170A3 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use |
| 04/28/2005 | US20050090752 Method for evaluating and treating hypertension |
| 04/28/2005 | US20050090693 Clusianon derivatives; anticarcinogenic, antitumor and viricidal agents; mixture with mitogen-activated protein (MAP) kinase inhibitors |
| 04/28/2005 | US20050090672 Intermediates for production of losartan; chloroformylation; hydroxylation; angiotensin II antagonists; hypertension |
| 04/28/2005 | US20050090671 for human telomeres/telomerases; drug screening |
| 04/28/2005 | US20050090669 Aminoalcohol derivatives as beta-3 adrenergic receptor agonists |
| 04/28/2005 | US20050090661 For use as heat shock protein expression promoter, cell injury/death inhibitor, and cell and tissue protecting agent (organ preservation agent), antiulcer agent, antihepatopathic agent, and interleukin production promoter |
| 04/28/2005 | US20050090564 Compositions and treatments of bacterial vaginosis |
| 04/28/2005 | US20050090562 1-benzoyl-8,8-dimethyl-2-hydroxy-3,5,7-tris(3-methyl-2-butenyl)bicyclo- [3.3.]non-2-ene-4,9-dione and a protein kinase inhibitor; antineoplastic agents; antiproliferative agents |
| 04/28/2005 | US20050090561 Cardiovascular disorders eg venous thrombosis, arterial thrombosis, deep vein thrombosis, pulmonary embolism, unstable angina, myocardial infarction, cardiac ischemia, occlusive diseases of the peripheral arteries and atrial fibrillation, smooth muscle cell proliferation, atherosclerosis, arteriosclerosi |
| 04/28/2005 | US20050090558 Suppressing immune response in a mammal comprising accelerating lymphocyte homing (ALH) to any of mesenteric or peripheral lymph tissues or Peyer's patches by administering an ALH-immunosuppressive compound |
| 04/28/2005 | US20050090557 Methods and compositions for administration of TRPV1 agonists |
| 04/28/2005 | US20050090556 Method for treatment of external secretion disorders |
| 04/28/2005 | US20050090555 Compound for the treatment of metabolic disorders |
| 04/28/2005 | US20050090554 Administering baclofen, or a salt thereof, to relieve at least one symptom of gastroparesis other than vomiting |
| 04/28/2005 | US20050090553 Compositions and method for treatment of chronic inflammatory diseases |
| 04/28/2005 | US20050090552 Crystalline form with xray powder diffraction pattern peaks at 4.7, 7.4, 13.8 and 17.0+-0.2 but not at 3.8+-0.2 theta; thermal stability |
| 04/28/2005 | US20050090551 Therapeutic use of methionine for the treatment or prevention of mucositis |
| 04/28/2005 | US20050090550 Treating and/or preventing urinary incontinence using prodrugs of GABA analogs |
| 04/28/2005 | US20050090549 Intrathecal gabapentin for treatment of pain |
| 04/28/2005 | US20050090548 Intrathecal gabapentin for treatment of epilepsy |
| 04/28/2005 | US20050090547 Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains |
| 04/28/2005 | US20050090545 Nitric oxide topical technology |
| 04/28/2005 | US20050090544 Oxaliplatin formulations |
| 04/28/2005 | US20050090543 Method for the preparation of tetrahydrobenzothiepines |
| 04/28/2005 | US20050090542 crystalline polymorphic dosage forms of anticholesterol agents; statins |
| 04/28/2005 | US20050090541 Indolinone derivatives and their use in treating disease-states such as cancer |
| 04/28/2005 | US20050090540 E.g., 2,2-bis(hydroxymethyl)-1 -azabicyclo[2,2,2]octan-3-one and 2-hydroxymethyl-3,3-dihydroxy-1-azabicyclo[2,2,2]octane; these compounds reactivate the apoptosis-inducing function of mutant p53 proteins and are used to treat various types of tumors |
| 04/28/2005 | US20050090539 Intermediates for making 1(alpha-amino-1-(cyclopropyl-fused pyrrolidinylcarbonyl)methyl)-3-hydroxyadamantanes, e.g., methyl 3-hydroxy-<a-oxotricyclo[3.3.1.13,7]decane-1-acetate |
| 04/28/2005 | US20050090538 Potentiating an NSAID and/or acetaminophen analgesic by administering concurrently a cyclooxygenase-2 inhibitor such as celecoxib, meloxicam, nimesulide and/or rofecoxib |
| 04/28/2005 | US20050090537 Pharmaceutical composition based on idazoxan, salts, hydrates or polymorphs thereof |
| 04/28/2005 | US20050090536 Substituted pyrrol-3-ylisoxazoles, e.g., N-benzyl-4-[4-(o-chlorophenyl)-5-isoxazolyl)pyrrole-2-carboxamide; treating diseases that are alleviated by a protein kinase inhibitor, particularly cancer, inflammatory disorders, restenosis, and cardiovascular disease. |
| 04/28/2005 | US20050090535 Epothilones C, D, E and F, preparation and compositions |
| 04/28/2005 | US20050090533 Treating schizophrenia by administering an N-(2-aminopyridin-5-yl)amino-phenylisobutyramide, e.g., N-[6-(2-acetylamino-ethylamino)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide |
| 04/28/2005 | US20050090532 Medicinal uses of dihydropyrazoles |
| 04/28/2005 | US20050090531 MAG expression promoters |
| 04/28/2005 | US20050090530 5-(4-(2-(n-methyl-n-(2-pyridyl)amido)ethoxy)benzyl)thiazolidine-2, 4-dione and pharmaceutical compositions comprising the same |
| 04/28/2005 | US20050090529 5-pyridin-3-yl-substituted, e.g., 5-(5-ethylaminomethyl-4-methylpyridin-3-yl)-3-(1H-imidazol-2-yl)-1H-indazole; CDK mediators, used to treat cancer, as well as proliferative diseases such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis |
| 04/28/2005 | US20050090527 H1 antagonists used include loratadine, desloratadine, cetirizine and fexofenadine; H3 antagonists used include thioperamide, impromidine, burimamide, clobenpropit, impentamine, and mifetidine; and H4 antagonists used include dual H3/H4 antagonists |
| 04/28/2005 | US20050090526 3-Cyano-7-methoxy-4-(3-bromo-4,5-dimethoxyphenyl)-2-oxo-2H-chromene; 7-Amino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-2-imino-2H-chromene; anticancer, antitumor agent |
| 04/28/2005 | US20050090525 carboxymethylated N-(nitrogen group functionalized alkyl- carbonylhydrazido)- or carbonylaminomethylcarbonyl)- substituted; integrin inhibitors used for combating thromboses, cardiac infarction, coronary heart diseases, arteriosclerosis, inflammation, tumors, osteoporosis, infections and restenosis |
| 04/28/2005 | US20050090524 Novel adamantane derivatives |
| 04/28/2005 | US20050090523 2-(substituted phenyl)imidazo[1,2-a]pyridine compounds; use to treat disorders mediated by the histamine H3 receptor such as sleep disorders, attention deficit hyperactivity disorder, or Alzheimer's disease; 2-[4-[3-(Piperidino)propylamino]phenyl]-8-methylimidazo[1,2-a]pyridine for example |
| 04/28/2005 | US20050090521 Tetrazoloquinoline, triazoloquinoline, and oxazoloquinoline compounds, e.g., 9-chloro-N-isopropoxytetrazolo[1,5-a]quinoline-4-carboxamide |
| 04/28/2005 | US20050090520 Treatment of disease or injury of the nervous system with FTY720 |
| 04/28/2005 | US20050090519 1-Alkyl-4-(3-substitutedphenyl)piperidines |
| 04/28/2005 | US20050090518 Method for treating parkinson's disease using apomorphine and apomorphine prodrugs |
| 04/28/2005 | US20050090517 Pharmaceutical combinations of cox-2 inhibitors and opiates |
| 04/28/2005 | US20050090516 Novel substituted imides |
| 04/28/2005 | US20050090515 anticarcinogenic, antitumor, antiproliferative agents; focal adhesion kinase (FAK) and cyclin-dependent kinase (CDK) enzyme inhibitors |
| 04/28/2005 | US20050090514 Cool-genic compounds as anticarcinogenic agents promoting apoptosis and inhibit angiogenesis; antiproliferative agents |
| 04/28/2005 | US20050090513 Compounds specific to adenosine a1 and a3 receptors and uses thereof |
| 04/28/2005 | US20050090512 Method of treating extreme physical or mental stress using L-theanine to obtain accelerated regeneration |
| 04/28/2005 | US20050090511 Synergistic combination of theanine and cystine for administration with foods, feeds, and beverages bases, confectioneries or powders; viricides, bactericides |
| 04/28/2005 | US20050090510 Use of low molecular weight compounds for preparing a medicament useful in treating mutant p53 mediated diseases |
| 04/28/2005 | US20050090507 Administered singly or in combination with a second antineoplastic agent; cyclin-dependent kinase inhibitors, antiproliferative agents; coupling and cyclization of a 1-aminopyridazinium salt with a 2-alkylthio-4-alkynyl pyrimidine compound |
| 04/28/2005 | US20050090505 Methods of reducing risk of infection from pathogens |
| 04/28/2005 | US20050090504 Crohn's disease, ulcerative colitis, asthma, hypersensitivity pneumonitis, eosinophilic pneumonias, rhinitis, psoriasis, dermatitis and eczema |
| 04/28/2005 | US20050090503 5-HT receptor ligands and uses thereof |
| 04/28/2005 | US20050090502 Protein tyrosine phosphatase 1B inhibitors alone or incombination with other antidiabetic, antilipemic, anticholesterol or hypotensive agents |
| 04/28/2005 | US20050090501 Heteroaryl-cyclic acetals |
| 04/28/2005 | US20050090500 Oral administration of a crystalline form of erlotinib hydrochloride to treat cancer expressing epidermal growth factor receptor (EGFR), including non-small cell lung cancer, head and neck cancer, or ovarian cancer |
| 04/28/2005 | US20050090499 Oral or injectable dosage forms; antiproliferative, anticarcinogenic, and antiinflammatory agents; ATP hydrolysis inhibition |
| 04/28/2005 | US20050090497 Novel ester or amide derivatives |
| 04/28/2005 | US20050090496 Sulphonyl compounds with 5-ht6 receptor affinity |
| 04/28/2005 | US20050090494 Such as N-[2-(3-{[1-(3,4-dichlorobenzylpiperidinyl]aminohydroxypropoxy)phenyl]acetamide; antiinflammatory agents, antiarthritic agents; chronic obstructive pulmonary disease, asthma, multiple sclerosis |